Pα+ Psychedelic Bulletin #153: MindMed Scraps Microdosing Program; Eagerly Anticipated Ibogaine Study Publishes; Compass Collaborates with Greenbrook; Gilgamesh’s GM-1020 Readout; and more… Post published:January 12, 2024 Post category:Psychedelic Bulletin/Pα+
Psychedelic Bulletin #152: Policy and Business Updates Post published:December 22, 2023 Post category:Psychedelic Bulletin
Pα+ Psychedelic Bulletin #151: Psilocybin for BDII, ACNP Readouts, Methylone for PTSD, and More Psychedelic Drug Dev. News Post published:December 14, 2023 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #150: Drug Development and Research Updates Post published:November 29, 2023 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #149: Worldwide Psychedelic Policy Developments Post published:November 17, 2023 Post category:Psychedelic Bulletin/Pα+
Psychedelic Bulletin #148 (Pα+) Post published:November 3, 2023 Post category:Psychedelic Bulletin/Pα+
Psychedelic Bulletin #147: Newsom Vetoes Psychedelic Decrim. in CA; At-Home Ketamine Gets a Lifeline and a Warning; Drug Development Updates from GH, atai, Cybin; and more Post published:October 17, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #146: Numinus Drops Lab, Consolidates Clinics; Study Suggests DMT Safe and Effective Alongside SSRI; Preprint Calls Intracellular Theory of Psychedelic-induced Neuroplasticity Into Question; A Cole Memo for Psychedelics? Post published:September 29, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #145: MAPS’ Second Phase 3 Study Published; EMA’s New Draft Guideline on Depression Drug Dev Includes Psychedelics; California’s Decrim. Bill Goes to Governor Post published:September 19, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft Guidance; Cybin to Acquire Small Pharma; Usona Publishes Phase 2 Study Post published:August 31, 2023 Post category:Psychedelic Bulletin